Religious communities around the US are getting hit with AI depictions of their leaders sharing incendiary sermons and asking for donations. “You’re being watched by a demonic human,” said the fake ...

As American University law professor Andrew Ferguson warned in 2024, the ease of automation can nudge officers to become less ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

If you are following Replimune Group (REPL) right now, you’re not alone. The company’s recent announcement about completing a Type A meeting with the FDA on its lead drug candidate, RP1, has put it ...

The fate of a once-promising cancer treatment now looks uncertain at best. The meeting was conducted with U.S. Food and Drug Administration (FDA) officials, and it took place on Tuesday. The subject ...

Welcome to the Replit desktop app for MacOS, Windows, and Linux. The app is developed using Electron and packaged and distributed using Electron Forge. You can then ...

Investing.com -- Replimune Group Inc (NASDAQ:REPL) stock tumbled 36% premarket after STAT reported that the FDA’s top cancer drug regulator intervened late in the review process of the company’s skin ...

Investor Action Alert – Undercard Stocks Breaking Out Beneath the Surface of the Mag 7 - While Big Tech's“Mag 7” continues to dominate headlines, a new wave of high-upside small- and mid-cap stocks is ...

Despite a sharp drop in the previous session following the FDA rejection of its skin cancer drug RP1, Replimune (NASDAQ:REPL) shares bounced back on Wednesday even as multiple Wall Street analysts ...

NEW YORK--(BUSINESS WIRE)--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Replimune Group, Inc. (NASDAQ: REPL) for potential violations of the federal ...

Replimune Group, Inc. (NASDAQ:REPL) stock plunged on Tuesday after a U.S. Food and Drug Administration (FDA) update. The clinical stage biotechnology company received an FDA Complete Response Letter ...

Investing.com -- Replimune Group, Inc. (NASDAQ:REPL) stock plunged 77% after the company announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) ...